Cannabis Patent Case Stayed: Metronome v. Smartscience Analysis Amid Bankruptcy

Introduction

A Florida federal court has administratively closed a cannabis-derived topical treatment patent infringement case after the defendant filed for bankruptcy — a procedural outcome that highlights the intersection of IP litigation and insolvency law that increasingly shapes patent disputes in the cannabis therapeutics sector.

Filed in the Middle District of Florida on July 16, 2025, Metronome, LLC v. Smartscience Laboratories, Inc. (Case No. 8:25-cv-01844) centered on alleged infringement of U.S. Patent No. US10653736B2, covering topical treatments incorporating cannabis sp. derived botanical drug products. The case was stayed and administratively closed on October 31, 2025 — just 107 days after filing — when Smartscience Laboratories triggered the automatic stay provisions of federal bankruptcy law.

For patent attorneys, IP professionals, and R&D teams operating in the cannabis pharmaceutical space, this case offers a practical study in litigation risk, bankruptcy strategy as a defensive tool, and the procedural framework courts apply when patent claims collide with insolvency proceedings. Cannabis-derived botanical drug patent litigation is an emerging and increasingly contested area, making this case a valuable data point for anyone tracking IP trends in this sector.

Case Overview

The Parties

The Patent at Issue

This case involved U.S. Patent No. US10653736B2 (Application No. US16/257389), covering topical treatments incorporating cannabis sp. derived botanical drug products. This patent protects formulations — creams, gels, or similar topical applications — that use cannabis-sourced compounds as active pharmaceutical ingredients.

• • US10653736B2 — Topical treatments incorporating cannabis sp. derived botanical drug products

Accused Products

The accused products were Smartscience Laboratories’ topical treatments incorporating cannabis-derived botanical drug ingredients — placing this dispute squarely within the growing market for cannabinoid-based therapeutics.

Legal Representation

Plaintiff was represented by attorneys Isaac Rabicoff of Rabicoff Law LLC and Terry Marcus Sanks of Beusse Sanks.

Defendant was represented by Jake C. Blanchard of Blanchard Law, P.A.

Litigation Timeline & Procedural History

The case moved with notable speed — reaching its procedural conclusion in just 107 days from filing. This compressed timeline was not driven by judicial efficiency or early settlement, but rather by Smartscience Laboratories’ bankruptcy filing, which triggered an automatic stay under 11 U.S.C. § 362 of the U.S. Bankruptcy Code.

Venue in the Middle District of Florida was a deliberate choice, a jurisdiction known for active patent dockets and experienced IP jurists. However, the substantive litigation — claim construction, infringement analysis, validity challenges — never advanced to the point where the court’s merits-based jurisprudence could be evaluated.

The 107-day duration is notably short even by patent litigation standards, where the average district court case runs 18–36 months. This reflects the preemptive effect of bankruptcy proceedings rather than any accelerated merits adjudication.

The Verdict & Legal Analysis

Outcome

The court did not issue a merits-based verdict. Instead, the Middle District of Florida directed the Clerk to stay and administratively close the case in light of Smartscience Laboratories’ pending bankruptcy proceedings.

The court’s order established a structured monitoring protocol:

• • Lead counsel for the plaintiff must file a status report on May 1, 2026, and every 180 days thereafter, advising on the status of the bankruptcy proceedings.
• • Within seven days of final judgment in the bankruptcy proceeding, plaintiff’s counsel must either move to reopen the patent case or inform the court of how the parties intend to proceed.

No damages were awarded, no injunctive relief was granted, and no infringement or validity findings were made. The case basis of termination is formally classified as Case Stayed.

Why the Bankruptcy Stay Controls

When a defendant files for bankruptcy, the automatic stay under § 362 immediately halts most civil litigation against the debtor. Patent infringement cases are not exempt. Courts are required to honor this statutory pause, redirecting the dispute — at least temporarily — into the bankruptcy forum where creditor claims are adjudicated collectively.

This creates a strategic dilemma for patent plaintiffs: their infringement claims become unsecured creditor claims in the bankruptcy estate, competing with other liabilities. Depending on the bankruptcy chapter and the debtor’s asset structure, a patent holder may recover cents on the dollar — or nothing — compared to what a successful infringement verdict might have yielded.

Legal Significance

While this case produced no precedential ruling on cannabis patent validity or infringement, it illustrates a critical procedural reality: patent litigation outcomes can be determined entirely by financial factors outside the merits of the IP dispute. The strength of US10653736B2’s claims — its scope, validity, and infringement read — remains entirely untested on the record.

For the cannabis pharmaceutical patent space, this means one of the sector’s infringement actions has been effectively suspended without any judicial guidance on how courts would construe cannabis-derived botanical drug formulation claims.

Strategic Takeaways

For Patent Holders: Before asserting infringement claims, conduct thorough financial due diligence on the defendant. A defendant’s bankruptcy filing can convert a strong patent case into a bankruptcy proof-of-claim process — a fundamentally different and often less favorable forum.

For Accused Infringers: Bankruptcy proceedings, while not a patent defense, can provide significant tactical relief — pausing litigation, restructuring liabilities, and potentially discharging infringement damages depending on claim classification and case chapter.

For R&D Teams: This case underscores that cannabis-derived topical formulations remain contested patent territory. Freedom-to-operate (FTO) analyses should specifically address US10653736B2 and related botanical drug formulation patents before commercializing cannabinoid-based topical products.

Industry & Competitive Implications

The cannabis therapeutics sector is navigating a uniquely complex IP environment. As the FDA continues developing regulatory pathways for botanical drug products, and as state-level legalization expands the commercial market for cannabis-derived treatments, patent activity in this space is intensifying.

Metronome v. Smartscience — though stayed — signals that patent holders are actively asserting rights over cannabis-derived topical formulation technologies. Companies operating in this market should anticipate continued assertion activity targeting products that incorporate cannabis sp. compounds in pharmaceutical-grade topical delivery systems.

The financial fragility evident in Smartscience’s bankruptcy also reflects broader market pressures in the cannabis industry, where regulatory uncertainty, capital constraints, and competitive commoditization have stressed many early-stage operators. When financially distressed companies hold or infringe valuable patents, litigation outcomes become deeply entangled with insolvency proceedings — a trend patent litigators in this sector must plan for proactively.

Licensing strategy deserves particular attention here. Patent holders like Metronome may find that pre-litigation licensing outreach offers more reliable value capture than infringement suits against defendants whose financial stability is uncertain.

FAQ

What patent was involved in Metronome LLC v. Smartscience Laboratories?
The case involved U.S. Patent No. US10653736B2 (Application No. US16/257389), covering topical treatments incorporating cannabis sp. derived botanical drug products.

Why was this case stayed and closed?
The court stayed the case due to Defendant Smartscience Laboratories, Inc.’s pending bankruptcy proceedings, which triggered an automatic stay under federal bankruptcy law, halting active civil litigation.

How might this case affect cannabis patent litigation strategy?
It highlights that patent plaintiffs must assess defendants’ financial health before filing, as bankruptcy can divert strong infringement cases into creditor proceedings where recovery is uncertain.

For deeper analysis of cannabis-derived pharmaceutical patent litigation, explore related cases at USPTO Patent Center or review case filings via PACER under Case No. 8:25-cv-01844, Middle District of Florida.

📌 Subscribe for patent litigation updates across cannabis, pharmaceutical, and botanical drug technology sectors. Contact our IP team for case analysis, FTO assessments, or patent assertion strategy in the cannabis therapeutics space. Explore related cases in botanical drug product patent litigation to benchmark your IP risk profile.